Wingate Wealth Advisors Inc. Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Wingate Wealth Advisors Inc. bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $437,000.

Several other large investors have also added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in Revolution Medicines in the 3rd quarter valued at $801,000. Citigroup Inc. grew its holdings in shares of Revolution Medicines by 29.5% in the 3rd quarter. Citigroup Inc. now owns 117,938 shares of the company’s stock valued at $5,348,000 after acquiring an additional 26,871 shares in the last quarter. State Street Corp increased its position in shares of Revolution Medicines by 4.1% in the third quarter. State Street Corp now owns 5,279,584 shares of the company’s stock valued at $239,429,000 after acquiring an additional 208,516 shares during the last quarter. Barclays PLC raised its holdings in Revolution Medicines by 187.1% during the third quarter. Barclays PLC now owns 294,664 shares of the company’s stock worth $13,362,000 after acquiring an additional 192,021 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Revolution Medicines by 58.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,763,117 shares of the company’s stock worth $79,957,000 after acquiring an additional 653,433 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, Director Thilo Schroeder purchased 1,304,347 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were acquired at an average cost of $46.00 per share, with a total value of $59,999,962.00. Following the completion of the transaction, the director now owns 2,096,612 shares in the company, valued at $96,444,152. The trade was a 164.64 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jack Anders sold 2,635 shares of Revolution Medicines stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the sale, the chief financial officer now owns 96,470 shares of the company’s stock, valued at $4,379,738. This trade represents a 2.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,678 shares of company stock worth $847,981 over the last quarter. Company insiders own 8.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on RVMD. Guggenheim raised their price target on Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Oppenheimer raised their target price on shares of Revolution Medicines from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. HC Wainwright upped their price target on shares of Revolution Medicines from $64.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Wedbush reiterated an “outperform” rating and issued a $70.00 price target on shares of Revolution Medicines in a research note on Monday, December 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $68.00 price objective on shares of Revolution Medicines in a research note on Tuesday, December 3rd. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $66.25.

Revolution Medicines Trading Down 3.2 %

Shares of RVMD opened at $42.19 on Monday. Revolution Medicines, Inc. has a 52 week low of $28.43 and a 52 week high of $62.40. The firm’s 50-day simple moving average is $43.67 and its 200 day simple moving average is $46.51.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.